PSY1 Association of Adverse Events And Health Service Usage With Tapentadol Prolonged-Release Treatment Compared With Morphine Controlled-Release (Cr) And Oxycodone Cr: A Uk Primary Care Observational Study  by Baxter, G et al.
A658  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
PMS138
ASSeSSMent of RiSk ShARing AgReeMentS (RSAS) in Select globAl 
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Objectives: To understand current Risk Sharing Agreements (RSAs) for immu-
nomodulators for rheumatoid arthritis, psoriasis, and psoriatic arthritis in 11 mar-
kets aimed to optimize specific RSA strategies/ payer partnerships. MethOds: 
Review of publicly available health authority websites and peer-reviewed journals. 
Interviews with payers and stakeholders who influence RSA decisions and ex-
pharma executives for validation and gap filling. Results: USA manufacturers 
negotiate RSAs with private health insurers and states. Payers in USA integrate 
financial risks with manufacturers using outcome based agreements (OBAs). Canada 
established RSAs with Provinces and use financial based agreements (FBAs) but 
some are OBAs. France requires volume based FBAs for new high-priced therapies 
to limit budget impact. Germany uses FBAs at the sickness fund level rather than 
the Gemeinsamer Bundesausschuss (G-BA) level because sickness funds manage 
their own budgets. Some OBAs exist with clearly defined outcomes. Italy negotiates 
RSAs at the national level for new therapies entering the market ranging from FBAs 
to OBAs depending on the specific therapy and target patient population. Italy may 
also require manufacturers to incorporate drug monitoring registries in the RSA. In 
Spain performance based OBAs are used for new therapies with nominal additional 
benefit at the regional level with clearly established outcomes. Netherlands and 
Sweden use evidence development (CED) agreements for high priced products to 
generate cost effectiveness data. In Switzerland, RSAs are new and mostly FBAs 
and mainly for orphan disease therapies and off-label indications with price cap-
ping. In the UK,FBAs with few OBAs are used affecting product price but are not 
rebate based. Australian RSAs are mostly FBAs and are referred to as “Deeds of 
Agreement.” cOnclusiOns: With high-cost immunomodulators, authorities are 
shifting towards integrating RSAs in price negotiations to optimize budget expec-
tations prior to launch. Europe prefers FBAs to OBAs which often require clearly 
defined outcomes.
SYSteMic diSoRdeRS/conditionS – clinical outcomes Studies
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Objectives: This study compared adverse outcomes and resource use in patients 
treated with tapentadol prolonged-release (PR) with those treated with morphine 
controlled-release (CR) and oxycodone CR. MethOds: Data were from the Clinical 
Practice Research Datalink, a database derived from UK primary-care. Patients pre-
scribed tapentadol PR between May 2011 and December 2014 were matched to two 
groups of controls treated with either morphine CR or oxycodone CR on gender, age, 
pain duration, pain site and aetiology, Charlson index and prior analgesia. Rates 
of adverse events (constipation and nausea/vomiting) were compared by adjusted 
hazard ratio (aHR). Rates of primary-care contacts, accident and emergency con-
tacts, outpatient clinic letters and, for a subset of patients linked to Hospital Episode 
Statistics (HES), inpatient admissions were compared using incident rate ratios (IRRs) 
derived from Poisson regression. Results: 1,176 patients prescribed tapentadol PR 
were identified; 1,103 (93.8%) had a pain diagnosis. Of these 789 (67.1%) were matched 
to morphine controls and 557 (47.4%) to oxycodone controls. Compared with con-
trols, adverse events with tapentadol PR treatment were reduced: aHR= 0.643 (95% 
CI 0.459–0.901; p= 0.010) versus morphine CR and 0.505 (0.335–0.763; p= 0.001) ver-
sus oxycodone CR. Compared with morphine CR, primary-care contacts (IRR= 0.817; 
0.786–0.850), accident and emergency attendance (0.699; 0.560–0.870) and outpatient 
letters (0.715; 0.543–0.939) were also reduced. For oxycodone CR, the respective figures 
were 0.776 (0.706–0.840), 0.840 (0.639–1.103) and 0.545 (0.400–0.739). For the subset of 
HES-linked patients the rates of inpatient admissions were 0.723 (0.590–0.884) and 
0.458 (0.357–0.585) vs. morphine CR and oxycodone CR, respectively. cOnclusiOns: 
Tapentadol PR was associated with significantly fewer adverse gastrointestinal events 
than morphine CR or oxycodone CR. There was also significantly reduced primary- 
and secondary-care resource use. As with all observational studies, potential bias 
due to residual confounding and confounding by indication should be considered.
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Objectives: To assess the clinical and economic burden of pulmonary exacerba-
tions (PEx) in patients with cystic fibrosis (CF) and homozygous for the F508del 
CFTR gene mutation. MethOds: Medical chart data from patients with CF ≥ 12 
years old were collected in France, Germany, Italy, Spain, Australia and Canada. 
Demographics, clinical characteristics, and selected resource utilization were 
obtained for a 12-month baseline period and a follow-up period ranging from 2-36 
months. The frequency of PEx and associated resource utilization was assessed 
overall and by age (12-17, ≥ 18 years) and lung function (percent predicted forced 
expiratory volume in 1-second [ppFEV1] ≥ 70%, 41-69%, ≤ 40%). Descriptive analyses 
were conducted. Results: Data for 523 patients were included. Baseline mean 
± SD age was 24.8 ± 9.5 years and mean ± SD ppFEV1 was 67.1 ± 22.9%. During 
disease activity and lab measurements. Results: 106 papers met our inclusion 
criteria. Studies were published between 2003 and 2015 and mostly from Europe; 
39 included patients starting etanercept, 36 included patients starting rituximab 
and 32 patients starting tocilizumab. Mean age ranged between 42.9 and 63.3 years, 
78.2% were female. The drugs were given in combination with methotrexate and/or 
other traditional DMARDs in over two thirds of the studies. Mean disease duration 
varied between 4 and 17.5 years, baseline disease activity 28 scores between 4.3 and 
7.0, and baseline health assessment questionnaire values between 1 and 2.9. The 
mean percentage of rheumatoid-factor positive patients was 76.4%. Reporting of 
comorbidities and smoking status was generally poor, with only few studies provid-
ing detailed data. cOnclusiOns: This systematic review of data from observational 
studies and clinical databases indicates that the characteristics of RA patients start-
ing biological DMARDs outside clinical trials in the real world varied widely. These 
observational data will now be compared with clinical trial data but it seems likely 
that some patient groups were not well represented in the trials.
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Objectives: Early diagnosis and treatment of inflammatory arthritis can limit 
the impact of disease outcomes. We aimed to evaluate the effectiveness of a 
referral program on the identification of patients with suspected inflammatory 
arthritis. MethOds: SIARA (Referral Strategies and Disease Education Impact 
on Diagnosis and Referral of Axial Spondyloarthritis and Rheumatoid Arthritis 
Patients) is an observational prospective, randomized (by clusters of primary care 
centers) study to analyze the impact of Referral Support Actions (RSA) consisting 
of physician educational sessions about the disease and implementation of referral 
recommendations. The participating primary care centers (n= 24) were randomly 
assigned to RSA or control group (with no intervention). Both RSA and control 
groups identified and referred patients with suspected inflammatory arthritis to 
the rheumatology unit of the reference hospital (n= 6). The main studied outcome 
is the correct diagnosis of inflammatory arthritis / rheumatoid arthritis confirmed 
by the rheumatologist of the reference hospital. Results: A total of 125 patients 
were referred to a rheumatologist (considering 4 hospitals): 61 RSA patients and 
64 control patients. Mean age was 48.9 years (range: 19-73) and 88.8% were female 
(differences not statistically significant between groups). About 14.8% (n= 9) of RSA 
patients and 4.7% (n= 3) of controls had a confirmed diagnosis of arthritis (any 
type) by the rheumatologist (OR= 3.5; 95%CI, 0.9-13.7; Chi-square p= 0.056). Rate 
of confirmed rheumatoid arthritis was 4.9% in RSA patients and 1.6% in controls 
(p= 0.287). The majority of the patients (82.0%) were referred in the 4 months after 
educational session (month 3:63.9%; month 6:96.7%). cOnclusiOns: Although the 
study results still lack statistical significance, this preliminary data already suggests 
a positive impact of a referral program on the early identification of inflammatory 
arthritis, especially after the first few months. This should be further analyzed and 
considered by healthcare deciders in order to improve health outcomes in inflam-
matory arthritis.
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Objectives: Several biosimilar products have been developed and marketed in 
Japan. However, the degree of understanding of biosimilars among healthcare pro-
fessionals is uncertain. The objective of this study was to investigate the extent 
of awareness and understanding of biosimilars among Japanese physicians and 
pharmacists. MethOds: This was a non-interventional, web-based survey con-
ducted in May 2015. Japanese physicians (rheumatologists/oncologists) and phar-
macists voluntarily participated and provided their thoughts via questionnaires. 
Rheumatologists who have seen > = 30 rheumatoid arthritis patients/month on aver-
age and have prescribed biologics (Remicade/Humira, etc.) to at least one patient, 
and oncologists who have seen > = 30 cancer patients/year with use of biologics 
(Rituxan/Avastin/Herceptin, etc.) to at least one patient were eligible. Results: Of 
screened physicians, about 35% have never heard of “biosimilar”, whereas 96% of 
pharmacists were aware of “biosimilar”. One hundred rheumatologists, 120 oncolo-
gists (30 each for Hematology/Breast/Gastroenterology/Respiratory) and 90 pharma-
cists who met the criteria and were aware of biosimilar were analyzed for a further 
questionnaire. 73% of rheumatologists and 82% of oncologists recognized that 
biosimilars “are relatively less expensive” and 62% of physicians simply answered 
“subsequent product/generic”. 58% of rheumatologists showed an intention to pre-
scribe future biosimilars, whereas 73% of oncologists showed prescription intention. 
The main reason behind this was “reduction of burden on patients”, followed by 
“confirmed similarity in efficacy/safety”. Physicians with little intention to prescribe 
biosimilars showed strong concerns for similarity to the innovator (> 70%) and insuf-
ficient clinical data in efficacy/safety perspectives. Similarities in clinical efficacy/
safety were more emphasized compared to structural and functional similarities 
in biosimilar development pathways. cOnclusiOns: Awareness of biosimilars 
amongst Japanese physicians was still low with a strong leaning toward burden on 
patients and sufficient clinical data to confirm the similarity. Providing learning 
opportunities for general tenets of biosimilarity and its development pathways are 
vital to increase public recognition of biosimilars.
